Official websites use. Share sensitive information only on official, secure websites. Correspondence: karim. Our work introduces a new robotic solution named CochleRob, which is used for the administration of super-paramagnetic antiparticles as drug carriers into the human cochlea for the treatment of hearing loss caused by damaged cochlea. This novel robot architecture presents two key contributions.
First, CochleRob has been designed to meet specifications pertaining to ear anatomy, including workspace, degrees of freedom, compactness, rigidity, and accuracy. The first objective was to develop a safer mathod to administer drugs to the cochlea without the need for catheter or CI insertion.
Secondly, we aimed at developing and validating the mathemathical models, including forward, inverse, and dynamic models, to support the robot function. Our work provides a promising solution for drug administration into the inner ear. Keywords: hearing loss, remote drug delivery, drug administration, cochlea, microrobots, magnetic actuator, medical robot, control.
The treatment of hearing loss due to inner ear damage has been a rapidly growing area of research and clinical trials in recent decades [ 1 ].
Many approaches have been proposed to treat different cochlear pathologies. Several robotic manipulators have been designed, and some of them have even been developed and tested in clinical studies [ 2 , 3 , 4 , 5 , 6 ]. The evolution of treatment approaches for cochlear pathologies has undergone two significant stages, moving from systemic administration to local administration. Based on the available information, researchers have proposed three methods of local administration: 1 transtympanic in situ drug administration method, which has limitations; 2 the catheter or CI implementation based method, which carries risk; and 3 the remote administration method, which is considered safe but requires a specialized robotic structure.
